claseprubart

Claseprubart is a potent, investigational, clinical-stage monoclonal antibody engineered to selectively inhibit only the active form of the human complement C1s protein, a clinically validated target in the classical pathway of the complement system. By binding to C1s, claseprubart blocks activation of the classical complement pathway, thus exerting immunosuppressive effects while preserving activity of the lectin and alternative pathways (important for limiting infection susceptibility). The molecule incorporates YTE half-life extension technology, enabling convenient subcutaneous self-administration as infrequently as once every two weeks. Claseprubart is being developed primarily for autoimmune neuromuscular diseases, with ongoing clinical trials in generalized Myasthenia Gravis (Phase 2), Chronic Inflammatory Demyelinating Polyneuropathy (Phase 3), and Multifocal Motor Neuropathy (Phase 2). The investigational status, selective mechanism, and dosing schedule may place it as a potentially best-in-class agent within its therapeutic area[1][2][5][7].

Other names

DNTH 103DNTH103DNTH-103